Abstract
Anti–PD1–based immune checkpoint blockade (ICB) treatment (Tx) is the standard therapy for R/M HNSCC but the objective response rate is low (<20%). Currently, PD-L1 expression is the only biomarker used in the clinic, however, the predictive value is low. The data on the correlation between ICB outcomes and genomic characteristics is scant. Here, we report a single institutional data of clinical outcomes and genomic characteristics of patients (pts) with R/M HNSCC treated with ICB-based therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
